Literature DB >> 17878169

The role of thrombin exosites I and II in the activation of human coagulation factor V.

Kenneth Segers1, Björn Dahlbäck, Paul E Bock, Guido Tans, Jan Rosing, Gerry A F Nicolaes.   

Abstract

Human blood coagulation Factor V (FV) is a plasma protein with little procoagulant activity. Limited proteolysis at Arg(709), Arg(1018), and Arg(1545) by thrombin or Factor Xa (FXa) results in the generation of activated FV, which serves as a cofactor of FXa in prothrombin activation. Both thrombin exosites I and II have been reported to be involved in FV activation, but the relative importance of these regions in the individual cleavages remains unclear. To investigate the role of each exosite in FV activation, we have used recombinant FV molecules with only one of the three activation cleavage sites available, in combination with exosite I- or II-specific aptamers. In addition, structural requirements for exosite interactions located in the B-domain of FV were probed using FV B-domain deletion mutants and comparison with FV activating enzymes from the venom of Russell's viper (RVV-V) and of Levant's viper (LVV-V) known to activate FV by specific cleavage at Arg(1545). Our results indicate that thrombin exosite II is not involved in cleavage at Arg(709) and that both thrombin exosites are important for recognition and cleavage at Arg(1545). Efficient thrombin-catalyzed FV activation requires both the N- and C-terminal regions of the B-domain, whereas only the latter is required by RVV-V and LVV-V. This indicates that proteolysis of FV by thrombin at Arg(709), Arg(1018), and Arg(1545) show different cleavage requirements with respect to interactions mediated by thrombin exosites and areas that surround the respective cleavage sites. In addition, interactions between exosite I of thrombin and FV are primarily responsible for the different cleavage site specificity as compared with activation by RVV-V or LVV-V.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17878169      PMCID: PMC2292461          DOI: 10.1074/jbc.M701123200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  47 in total

1.  Inhibitory sequences within the B-domain stabilize circulating factor V in an inactive state.

Authors:  Hua Zhu; Raffaella Toso; Rodney M Camire
Journal:  J Biol Chem       Date:  2007-03-26       Impact factor: 5.157

2.  Bovine factor X 1 (Stuart factor). Mechanism of activation by protein from Russell's viper venom.

Authors:  K Fujikawa; M E Legaz; E W Davie
Journal:  Biochemistry       Date:  1972-12-19       Impact factor: 3.162

3.  The subunit structure of thrombin-activated factor V. Isolation of activated factor V, separation of subunits, and reconstitution of biological activity.

Authors:  C T Esmon
Journal:  J Biol Chem       Date:  1979-02-10       Impact factor: 5.157

4.  The calcium-binding properties of bovine factor V.

Authors:  L S Hibbard; K G Mann
Journal:  J Biol Chem       Date:  1980-01-25       Impact factor: 5.157

5.  The contribution of bovine Factor V and Factor Va to the activity of prothrombinase.

Authors:  M E Nesheim; J B Taswell; K G Mann
Journal:  J Biol Chem       Date:  1979-11-10       Impact factor: 5.157

6.  Human coagluation factor V purification and thrombin-catalyzed activation.

Authors:  B Dahlbäck
Journal:  J Clin Invest       Date:  1980-09       Impact factor: 14.808

7.  A comparison of human prothrombin, factor IX (Christmas factor), factor X (Stuart factor), and protein S.

Authors:  R G Di Scipio; M A Hermodson; S G Yates; E W Davie
Journal:  Biochemistry       Date:  1977-02-22       Impact factor: 3.162

8.  Removal of B-domain sequences from factor V rather than specific proteolysis underlies the mechanism by which cofactor function is realized.

Authors:  Raffaella Toso; Rodney M Camire
Journal:  J Biol Chem       Date:  2004-03-05       Impact factor: 5.157

9.  The role of phospholipids and factor Va in the prothrombinase complex.

Authors:  J Rosing; G Tans; J W Govers-Riemslag; R F Zwaal; H C Hemker
Journal:  J Biol Chem       Date:  1980-01-10       Impact factor: 5.157

10.  Molecular properties of the Factor V-activating enzyme from Russell's viper venom.

Authors:  W Kisiel
Journal:  J Biol Chem       Date:  1979-12-10       Impact factor: 5.157

View more
  17 in total

1.  Restoring the procofactor state of factor Va-like variants by complementation with B-domain peptides.

Authors:  Matthew W Bunce; Mettine H A Bos; Sriram Krishnaswamy; Rodney M Camire
Journal:  J Biol Chem       Date:  2013-09-06       Impact factor: 5.157

2.  Thrombin-dependent MMP-2 activity is regulated by heparan sulfate.

Authors:  Bon-Hun Koo; Jung Ho Han; Young Il Yeom; Doo-Sik Kim
Journal:  J Biol Chem       Date:  2010-11-01       Impact factor: 5.157

3.  Occlusion of anion-binding exosite 2 in meizothrombin explains its impaired ability to activate factor V.

Authors:  Harlan N Bradford; Sriram Krishnaswamy
Journal:  J Biol Chem       Date:  2018-12-21       Impact factor: 5.157

4.  A high affinity, antidote-controllable prothrombin and thrombin-binding RNA aptamer inhibits thrombin generation and thrombin activity.

Authors:  K M Bompiani; D M Monroe; F C Church; B A Sullenger
Journal:  J Thromb Haemost       Date:  2012-05       Impact factor: 5.824

5.  A bipartite autoinhibitory region within the B-domain suppresses function in factor V.

Authors:  Mettine H A Bos; Rodney M Camire
Journal:  J Biol Chem       Date:  2012-06-15       Impact factor: 5.157

6.  Notecarin D binds human factor V and factor Va with high affinity in the absence of membranes.

Authors:  Jennifer L Newell-Caito; Malabika Laha; Anthony C Tharp; Jonathan I Creamer; Hong Xu; Ashoka A Maddur; Guido Tans; Paul E Bock
Journal:  J Biol Chem       Date:  2011-09-12       Impact factor: 5.157

7.  Structural basis of thrombin-mediated factor V activation: the Glu666-Glu672 sequence is critical for processing at the heavy chain-B domain junction.

Authors:  María Ángeles Corral-Rodríguez; Paul E Bock; Erick Hernández-Carvajal; Ricardo Gutiérrez-Gallego; Pablo Fuentes-Prior
Journal:  Blood       Date:  2011-05-09       Impact factor: 22.113

8.  Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency.

Authors:  Connie Duckers; Paolo Simioni; Luca Spiezia; Claudia Radu; Sabrina Gavasso; Jan Rosing; Elisabetta Castoldi
Journal:  Blood       Date:  2008-08-11       Impact factor: 22.113

Review 9.  The molecular basis of factor V and VIII procofactor activation.

Authors:  R M Camire; M H A Bos
Journal:  J Thromb Haemost       Date:  2009-09-18       Impact factor: 5.824

10.  Factor Xa activation of factor V is of paramount importance in initiating the coagulation system: lessons from a tick salivary protein.

Authors:  Tim J Schuijt; Kamran Bakhtiari; Sirlei Daffre; Kathleen Deponte; Simone J H Wielders; J Arnoud Marquart; Joppe W Hovius; Tom van der Poll; Erol Fikrig; Matthew W Bunce; Rodney M Camire; Gerry A F Nicolaes; Joost C M Meijers; Cornelis van 't Veer
Journal:  Circulation       Date:  2013-07-01       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.